Healthcare Services Group reported third-quarter 2026 revenue of $479.6 million , up about 3.3% from $464.3 million a year earlier. Diluted earnings per share (EPS) came in at $0.36 , down from $0.59 in the prior-year quarter but well ahead of analyst expectations.
Guardian Pharmacy Services (GRDN) traded near $40 in late October 2026, roughly 10% below its mid-September peak as the stock cooled off after a sharp rally. Over the trailing 30 days, shares pulled back about 9.8% from the September 21 close of $44.16, keeping the stock in consolidation territory rather than a breakout.
GRDN is trading down -5.4% at $39.61 during regular market hours, after closing the prior session at $41.87 (+4.31%). The move is intraday selling, not premarket or after-hours, with shares sliding through the morning session.
Both NIVF and TCRT are low-priced, micro-cap healthcare names that have experienced extreme volatility and Nasdaq listing-related uncertainty in recent months. NIVF is pivoting from fertility services toward a technology- and digital-asset-driven model, a transformation that has reshaped its market positioning but not yet stabilized its share price.
BMEA is a clinical-stage biopharmaceutical company pursuing oral treatments for diabetes and obesity, while NIVF is a fertility-services operator that has pivoted toward a diversified holding-company model spanning IVF, digital assets, artificial intelligence (AI), and real estate. Both names are speculative, low-priced micro-caps, but their risk profiles differ sharply: BMEA carries clinical-development risk, whereas NIVF carries significant dilution, capital-structure, and going-concern-type risk.
Different risk profiles: BKHA is a pre-merger SPAC (special purpose acquisition company), while NIVF is an operating fertility-services business. BKHA's defining catalyst is its pending business combination with preclinical biotech Vesicor Therapeutics, with the combined company expected to trade as "VESI."
HUBC (Hub Cyber Security) operates a focused cybersecurity and confidential computing business, while NIVF (NewGenIvf Group) has evolved from fertility clinics into a diversified holding company touching AI, digital assets, and real estate. Both are Nasdaq-listed micro-capitalization names that have executed reverse stock splits in recent quarters, a sign of sustained price pressure and shareholder dilution risk.
NIVF is a Thailand-based assisted-reproduction (fertility treatment) provider, while YFOR is a Singapore-based workforce management and integrated facility management (IFM) company pivoting toward AI, automation, and human-robot staffing. The two companies operate in unrelated sectors—healthcare services versus business/technology services—making this a contrast in business models rather than a like-for-like peer comparison.
NIVF (NewGenIvf Group) is a micro-cap fertility and technology-focused healthcare company, while ZBAO (Zhibao Technology) provides digital insurance brokerage and underwriting services in China. Both stocks have experienced sharp price declines and elevated volatility over the trailing 12 months, making this comparison most relevant to risk-tolerant, momentum-oriented traders.
CDT is a clinical-stage biopharmaceutical developer repositioning deprioritized drug candidates, while NIVF is a diversified growth company pivoting from fertility services into real estate, digital assets, and AI. Both stocks are Nasdaq-listed micro-caps with elevated volatility and recent share-structure changes, making them high-risk, event-driven names rather than steady compounders.
NIVF (NewGenIvf Group Limited) is a Thailand-based fertility-services operator, while RPGL (Republic Power Group Limited) is a Singapore-based enterprise-software provider — two micro-cap names with very different business models and risk profiles. Both stocks trade on the Nasdaq Capital Market and have executed multiple reverse stock splits in recent months, a pattern that typically signals sustained downward price pressure and capital-structure stress.
NIVF is pivoting from an Asia-Pacific fertility-services business into a diversified digital-asset, AI, and real-estate holding company, a transformation that has driven extreme volatility. NWGL is a vertically integrated forestry and wood-products company, a more traditional operating model with cyclical commodity exposure.
NIVF (NewGenIvf Group) and WFF (WF Holding) are both Nasdaq Capital Market micro-cap stocks that have completed reverse stock splits in recent months to maintain listing compliance. Both names have experienced severe, sustained share-price declines over the trailing 52 weeks, reflecting heavy dilution, financing overhangs, and highly speculative trading conditions.
Different industries, similar profiles: HUBC is an Israel-based cybersecurity and confidential-computing provider, while NIVF operates fertility clinics across Asia. Both are Nasdaq micro-caps that have used reverse stock splits to maintain listing compliance, underscoring elevated execution and liquidity risk in each name.
NIVF (NewGenIVF Group) and ZBAO (Zhibao Technology) are both Nasdaq-listed micro-cap stocks with elevated volatility and recent trading halts, making them more suited to risk-tolerant traders than to conservative investors. The two companies operate in fundamentally different industries: NIVF is pivoting from assisted-reproductive services into real estate, digital assets, and artificial intelligence, while ZBAO is a China-based digital insurance brokerage (insurtech) platform.
BKHA is a special purpose acquisition company (SPAC) completing a business combination with preclinical biotech Vesicor Therapeutics, with the combined company set to list under a new symbol. NIVF is a Bangkok-based company that has pivoted from fertility services toward AI, digital assets, and real estate, while its share price has declined sharply and undergone reverse stock splits.
FBGL (FBS Global) is a Singapore-based green building and interior fit-out contractor, while NIVF (NewGenIvf Group) is an assisted-reproduction and fertility-services provider across Southeast Asia. Both are Nasdaq Capital Market micro-caps that recently relied on reverse stock splits to address exchange listing requirements.
NIVF is a Thailand-based assisted-reproduction (fertility) services provider, while WFF is a Malaysia-based manufacturer of fiberglass reinforced plastic (FRP) industrial products — two fundamentally different business models. Both stocks are Nasdaq Capital Market micro-caps that have executed reverse stock splits in recent quarters to maintain the exchange's $1.00 minimum bid-price listing requirement.
Biomea Fusion (BMEA) is a clinical-stage biopharmaceutical company advancing oral small-molecule therapies for diabetes and obesity, while NewGenIvf Group (NIVF) is a Thailand-based fertility-services operator that has diversified into digital assets, artificial intelligence (AI), and real estate. BMEA's recent market activity has been driven by Phase 1 data for its oral GLP-1 (glucagon-like peptide-1) candidate, BMF-650, with the shares pulling back after mixed readouts.
JBDI is a Singapore-based industrial container reconditioning and recycling company now attempting a dramatic pivot into consumer artificial intelligence (AI). NIVF is a fertility-services provider operating in Hong Kong and Thailand, focused on in vitro fertilization (IVF) and related treatments.